Thank you Jen.
must As going order on cancer. were to been If defeat to go can already. on a is for it in easy do lot it, you see, us and a it would've lot done
So, it by isn't. definition
all immuno-oncology key very and the design agents. Jen attributes accomplishments, advantages But our including summarized of well of our
a lot have antibodies, our on portfolio. advanced lot our of checkpoint a we most the of deservedly the and in they are clinic emphasis there them While so put because are in
format cell the portfolio targets. allogeneic include much, very our significance not of therapies, We our our we which rest of our overlook the IO proprietary innovation. haven't of cell about which particularly These talked includes must also
this file therapy to expect first our cell year. IND We
targeting our in vaccines is our off-the-shelf important proprietary Also PTTs. our portfolio
about bit. a hear You’ll that more in
As Jen our on vaccines IND we these recently. mentioned, filed first class of very
refer to I slide our on, go that I the Before like exemplifies innovation. you to would
to little value. on a and to has is why differently. operationally reflect a of what between happened there going going with Agenus we're our and do We're accomplishments some disconnect bit things So the
to the one in INDs this filed number are of to here, thing, manufacturing innovation capabilities, our and number chart immuno-oncology can larger in slide So INDs refer development of much the IO companies. past represents It first I leading shows exemplifies in see the as performance years that that if you and in have number we immuno-oncology can bar half you the our relative in been filed three the and
To be for a we of in INDs Certainly, size of peers pleased discoveries resources and patients. of our our the is are to industry to miracle. XX performance delivering able a nothing by advance short company
are We science. developing this We with tremendous drugs and innovating frankly our conviction. and it. good We're and at are speed performance damn doing control we
contributions our evident to As as who our are Gilead. progress this is chart our partner partners and recent Merck here proprietary our and and most including pipeline displays, our represented Incyte in well
milestone has generated execution payments. milestones Our and
earlier. achievement morning, Gilead collaboration X-XBB our a of the milestone the also we a Jen in spoke as known fact, IND As of matter another call before that our of with AGENXXXX acceptance this CDXXX about molecule announced differentiated
with review at caps completed Next We companies you were the of performance, why stock market a stellar such is that cap that may operational at end relative Agenus have it price detailed $XXX and ask of as remained of depressed? has June. valued market IO million to up
aspects outperforming, company. our of the are Here
So peers in the in cap of below we outperformed months. have market last companies our XX XXX million
years higher We've of add list And in market past of this two values year. gone much year a companies some the and the to No. from ago. had ago No. on that I caps might X X
our be a to innovate. us. company our of is substantially portfolio the based to and and comfort this continue on ability of point course, not higher believe for We Of resources should value our
is the that performance lack products. important breakthrough due However, commercial of group immune-oncology innovations peer the has generation it know to the to industry first successes of suffered after and the
wall. hit is a perception has immune oncology that the So,
on our in most in that there fact, field. given out up some analysts conversations of they've In Street, on coming more notable the recently anything will no the immuno-oncology. is And expecting Wall remarkable pretty be consensus much with innovations perhaps
in It never pervasive perception the perception this wrong. wrong XX is believe immuno-oncology was as ago a the that when treatment is of cancer. be would people just We years believed as factor
recent immuno-oncology the the why and is of why is Here we wrong. record believe perception
Of come just the our the health, is bit. solution course to about a our but in believing will perception we situation, wrong
like after well and were The low fruit. CTLA-X researched. agents first went and PD-X IO the generation Companies that well comprise targets established hanging
The sparse. still young IO academic the as expertise companies well research as and of field relatively in large institutions is small is still and and
knowledge generation immuno-oncology use So been including how right innovation determining combinations them, the in with importantly where on to has when agents and the most and slow second in coming.
of underperformed and because capitalists in frenzy have the the Investors therapy of first from few. very apart been a has generation products success cell group companies, feeding venture engaged and the select disappointed
answer The Agenus immuno-oncology group large absolutely the year. stocks at fact, alike, of small the out in months. that you and to we satisfying companies traditional But in have past if XX outperformed performance is top yes no. IO again, the Once past four is In us? XX the IO the of look is
value to be will to pipeline next to key the you We may what novel ask, our where So, belongs? it our expect change creation. question is value broad get for and driver the
Our pipeline following in is slide. shown the
Our clinical and active data we'll and in many in or unprecedented of clinical of bring data immuno-oncology already a and next delivered today. that engine in such these XX time. our coming points XX from less development INDs I is industry up potential are has XX the months period The history believe short programs in
significant also will antibodies wholly-owned some additional cash. There there which have our fixed on these of see shown is for balance all number we in cash And us. forward, with drive implications The assets advancing transactions of you be balance can from will collaborations expect of assets a are clinical portfolio total no this This pipeline significant. us are in with development. nice in going partnered pipeline, partner But we our a slide. upfront very burden collaborations a
to expect upfronts. we be Some substantial
of in of to transactions some with our benefit business our ex-U.S. blockbuster more status including We from meaning with cash an these Agenus cancer in to remain be you. needed flows the to the us the we future and to substantial agents expect us for increasingly profit and for reinvest commercial of provide potential centric, intent of rights expect eradicate build for with and to all future will I-O assets to stakeholders a future the U.S. benefit more Agenus
now gears status me tell achieved you Let the and number filings one have we switch IND innovative for how therapies. in
advantages would quickly cell to and with a build also internal to at possible and These key GMP from ability quality capabilities line a much larger at to programs integrated lower allow manufacturing manage without are antibody discoveries development development than to portfolio capabilities. products us higher been lower our and efficiencies Our discovery have costs. pipeline of and cost of to these
products. job years we and Our few plan the invent at said and last earnings past more. INDs advance we a filing XX call, on have highlights, to half we in A advanced novel and is our three three
additional two include file have on and delivered of therapy others. cell among fact, In allogeneic already to before IND we year-end. these INDs These two INDs expect our
In for ideally a Paisley both and you solid may targets will antigen via phosphorylated proprietary and our to suited for platform about is safety. vaccines targets. terms be therapy tumors education powerful cancer cell few antigen These are also minutes immune potentially which of Dr. hear Myers for in for speak They us. efficacy discovery,
mentioned, patients in we very register to the agents. and Jen second We to to our a U.S. access with also we and line that CTLA-X develop, to footprint and partnerships plan explore allow our of As U.S. of the believe in importantly, PD-X our the launch Rest the World cervical indication will outside cancer. expand first
Remember, XX% rates are disease opportunity our improve responses short believe we the medicine combination Cervical We're to essentially not some and up We a talking cures in relatively even part XX% with we're is response strategy. about responses about to these difficult cancer monotherapy. that best and with cures. lived. perhaps an PD-X available talking have delivers
opportunity with on combinations, that the pursuing CTLA-X also by and these expand provide for market our our cervical plan specifically can generation many to cancer, potentially on with own we us the targeting agents cancers. PD-X which our for note, other other second And significantly beyond cancers
and a significant on vaccines impact of patients the words Before cancer the that XXXX. technology are to made team cell acquisition I patients. science have from all that and elegant Dr. turn and the innovations for benefit in PhosImmune. about we can Don a PhosImmune world-class the few is This Hunt’s Myers, Dr. Lab, driving valuable scientists Paisley therapies, call cancer cancer all to proprietary
Dr. these of Myers. One scientists is pursuing innovations the Paisley
science. as for Paisley? will with Paisley us of earnings enable her conquered pristine cancer. pristine technology describe our disease We with can can She's medicines appearance. of this that science only with effective represents features the of today be the this nasty I-O. work platform call simple dogged with in first pursuance Paisley’s more patients believe
